In breast cancer, pancreatic cancer, and other solid tumors, high tumor CCL2 expression is associated with improved responsiveness to CCR2 or CSF1R inhibitors, indicating that CCL2 expression levels may serve as a predictive biomarker concerning the efficacy of TAM‐targeted therapy [213]. Here, CCL2 is linked to familial pancreatic carcinoma.